8-K/A: STAAR Surgical Revises APAC Growth Outlook, Maintains Full-Year Sales Guidance

STAAR Surgical updated its financial outlook for fiscal year 2024, adjusting APAC regional growth assumptions while reaffirming its overall net sales guidance of $340 million to $345 million.

Summary

• STAAR Surgical has released an amended 8-K filing to correct inconsistencies in its previously reported financial outlook.
• The company's net sales outlook for fiscal year 2024 remains unchanged at $340 million to $345 million.
• The updated outlook reflects changes in regional growth assumptions for EVO ICL sales.
• Americas growth is now expected to be 17%, up from 15%, including 20% in the U.S., down from 25%.
• EMEA sales growth is projected at 10%, increased from 6%.
• APAC sales growth is revised to 5%, down from 7%, with China expected to grow by approximately 2%, down from 10%, and all other APAC countries growing by approximately 10-20%, up from flat.
• Third quarter net sales were $88.6 million, a 10% increase year-over-year.
• ICL sales were $89.1 million, also up 10% year-over-year.
• The company reported a net income of $10.0 million, or $0.20 per share, up from $4.8 million, or $0.10 per share, in the prior year quarter.
• Adjusted EBITDA was $16.2 million, or $0.33 per share, compared to $16.5 million, or $0.33 per share, in the prior year quarter.
• Cash, cash equivalents, and investments available for sale totaled $236.0 million as of September 27, 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company maintains its overall sales outlook and shows strong growth in some regions, the significant reduction in China's growth forecast and the decrease in gross margin temper the positive aspects.

Positives

• The company achieved double-digit sales growth in the third quarter.
• Net income per share increased significantly year-over-year.
• The company has a strong cash position with $236.0 million in cash, cash equivalents, and investments.
• The company is seeing increased adoption of EVO ICL for moderate myopia.
• The company is experiencing strong growth in the EMEA region.
• The company is maintaining its full year sales and adjusted EBITDA outlook.

Negatives

• Gross profit margin decreased to 77.3% from 79.2% in the prior year quarter due to reduced unit production.
• Operating income decreased to $5.7 million from $6.3 million in the prior year quarter.
• The company experienced a softening macroeconomic environment in the second half of the quarter, particularly in China.
• The company has reduced its growth outlook for China to approximately 2%.

Risks

• Global economic conditions could impact the company's performance.
• The company is dependent on demand from Asia, particularly China.
• Regulatory approvals for new products could be delayed or denied.
• International conflicts and trade disputes could affect the company's operations.
• The willingness of surgeons and patients to adopt new products and procedures is a risk.

Future Outlook

The company maintains its full-year net sales outlook of $340 million to $345 million and Adjusted EBITDA of approximately $42 million, or $0.80 per diluted share. The outlook includes revised regional growth assumptions for EVO ICL sales.

Management Comments

• In the third quarter, we achieved double-digit sales growth against a macroeconomic environment that softened in the second half of the quarter, particularly in China.
• STAAR is well positioned to navigate through the current market dynamics, which we believe are transitory.
• Looking ahead, we are encouraged by the recent shift in fiscal policy and announced stimulus in China and will continue to closely monitor the potential impact on our near to midterm growth outlook.
• Our focus on customer engagement and market expansion continues to yield solid results, helping drive industry-leading growth and market share gains.
• As our surgeon customers perform more EVO procedures, they are increasingly using our technology for moderate myopia, which underscores EVO ICL as the treatment choice for -6D and above and expands our total addressable market.

Industry Context

The announcement comes amid a generally softening market for refractive procedures, particularly laser vision correction, which declined 18% in the U.S. in Q3 2024. STAAR's ICL sales growth, despite these headwinds, indicates a strong market position and increasing adoption of their technology.

Comparison to Industry Standards

• While specific competitor data is not provided, the document notes that U.S. refractive procedures, predominantly laser vision correction, declined 18% in Q3 2024, while STAAR's U.S. ICL sales grew by 16%.
• This suggests that STAAR is outperforming the broader market in the U.S.
• The company's global ICL sales growth of 10% also appears strong compared to the overall market trends.
• The document mentions that EMEA laser vision correction procedures were flat to down 5% in Q3 2024, while STAAR's EMEA ICL sales grew by 12%, indicating a similar outperformance in that region.
• The company's focus on the -6D and above market segment is a strategic move to capture a specific niche within the refractive surgery market.

Stakeholder Impact

• Shareholders may react to the revised APAC growth outlook, particularly the reduced forecast for China.
• Employees may be affected by the company's performance and strategic shifts.
• Customers (surgeons and patients) will benefit from the company's continued focus on innovation and market expansion.
• Suppliers may be impacted by changes in production and sales volumes.

Next Steps

• The company will continue to monitor the impact of fiscal policy and stimulus in China.
• The company will focus on customer engagement and market expansion.
• The company will continue to invest in customer education, innovative tools, and practice support.

Key Dates

Keywords

EVO ICL, Implantable Collamer Lens, Ophthalmology, Refractive Surgery, Net Sales, Adjusted EBITDA, APAC, EMEA, Americas, China, Financial Outlook